GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
作者
Gemma Eminowicz,Nicole Concin,Lynda M. McSorley,Vojtech Tlustý,Flora Zagouri,Emad Matanes,Maria Cristina Petrella,Elisabeth Berge Nilsen,Keiichi Fujiwara,Jian 鄄 Liu Wang,Chien‐Hsing Lu,Atthapon Jaishuen,M. Valeria Cáceres,Sarah Crafton,Destin R. Black,Brian M. Slomovitz,Robert J. Orlowski,Stephan Kruger,Lili Yao,Bradley J. Monk